What it's for (Indications)
- Allopurinol is clinically indicated for the management of hyperuricemia, a condition characterized by abnormally high levels of uric acid in the blood.
- Its primary uses include the chronic management of gout and its various manifestations, such as gouty arthritis, tophi, and uric acid nephrolithiasis (kidney stones).
- Furthermore, it is prescribed for the prophylaxis of uric acid nephropathy, particularly in patients undergoing chemotherapy for leukemias, lymphomas, and other malignancies where rapid cell turnover leads to a significant increase in uric acid production.
- Allopurinol is also utilized in the treatment of primary or secondary hyperuricemia associated with certain enzyme deficiencies, such as Lesch-Nyhan syndrome, and for the prevention of recurrent calcium oxalate renal stones in patients who exhibit hyperuricosuria and have failed conventional therapeutic approaches.
- The goal of therapy is to reduce serum uric acid levels below the saturation point to prevent crystal formation and dissolution of existing crystals, thereby mitigating disease progression and symptoms.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of allopurinol must be individualized based on the patient's serum uric acid levels, renal function, and the specific indication. For the treatment of gout, initiation typically involves a low dose, such as 100 mg once daily, which is gradually increased by 100 mg increments at weekly intervals until a satisfactory serum uric acid level (usually below 6 mg/dL) is achieved. Maintenance doses commonly range from 200 mg to 800 mg daily, which may be administered as a single dose or divided. In cases of malignancy-related hyperuricemia, dosages may be higher, typically 600-800 mg daily, commenced 2-3 days prior to chemotherapy and continued during the treatment period, alongside adequate hydration. Significant dose reduction is imperative in patients with impaired renal function to prevent drug accumulation and minimize adverse effects; for example, patients with a creatinine clearance of 10-20 mL/min may receive 200 mg/day, while those with less than 10 mL/min may require 100 mg/day or less frequently. Pediatric dosing for malignancy-related hyperuricemia is typically 10-20 mg/kg/day or 100-200 mg/m²/day, divided into 2-3 doses, with a maximum of 600 mg/day. Slow titration and careful monitoring are crucial, especially in susceptible populations. |
Safety & Warnings
Common Side Effects
- Allopurinol can cause a range of side effects, with dermatological reactions being among the most common and clinically significant.
- Mild maculopapular or pruritic rashes occur frequently and generally necessitate immediate discontinuation of the medication.
- Gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort are also commonly reported.
- Other less frequent but notable side effects include drowsiness, headache, and taste perversion.
- Of greater concern are severe and potentially life-threatening reactions, including Allopurinol Hypersensitivity Syndrome (AHS), characterized by severe dermatologic reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), fever, eosinophilia, vasculitis, lymphadenopathy, hepatitis, and acute interstitial nephritis.
- Hematologic adverse effects such as bone marrow suppression (leukopenia, thrombocytopenia, aplastic anemia) can occur, necessitating regular blood count monitoring.
- Hepatic impairment, including elevated liver enzymes and cholestatic jaundice, and renal impairment are also possible.
- Long-term use has been associated with cataracts in some instances.
- Patients must be advised to report any adverse reactions promptly.
Serious Warnings
- Black Box Warning: Allopurinol does not carry a formal FDA-mandated Black Box Warning. However, it is imperative to acknowledge that allopurinol is associated with severe and potentially fatal hypersensitivity reactions, which warrant an equally serious level of attention and clinical vigilance. These include severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Allopurinol Hypersensitivity Syndrome (AHS). These reactions are characterized by a combination of fever, widespread severe skin rash (often blistering or exfoliating), eosinophilia, vasculitis, lymphadenopathy, hepatitis, and acute interstitial nephritis. The risk of these severe reactions is substantially elevated in patients with impaired renal function, those initiated on high doses of allopurinol, and individuals who carry the HLA-B*5801 allele, particularly among Han Chinese, Korean, and Thai populations. Treatment must be discontinued immediately at the earliest appearance of a skin rash or any other sign suggesting hypersensitivity. Re-initiation of allopurinol therapy following a severe hypersensitivity reaction is absolutely contraindicated due to the high likelihood of recurrence and the potential for fatal outcomes. Patients and caregivers must be educated on the signs and symptoms of these serious reactions and instructed to seek immediate medical attention should they occur.
- Several critical warnings are associated with allopurinol therapy.
- The most serious concern is the potential for severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Allopurinol Hypersensitivity Syndrome (AHS).
- These reactions can be fatal; therapy must be discontinued at the first sign of rash or any other symptom indicative of a hypersensitivity reaction.
- Patients with impaired renal function, those initiating therapy with high doses, and individuals of certain ethnic backgrounds (e.
- g.
- , Han Chinese, Korean, Thai) carrying the HLA-B*5801 allele are at increased risk.
- Dosage adjustment is essential in renal impairment to prevent drug accumulation and toxicity.
- Allopurinol should not be initiated during an acute gouty attack; prophylactic colchicine or NSAIDs are often co-administered during the initial months of therapy to prevent precipitation of acute flares.
- Adequate fluid intake (2-3 liters/day) is recommended to prevent uric acid stone formation and maintain urine volume.
- Significant drug interactions exist, notably with azathioprine and mercaptopurine, whose dosages must be drastically reduced due to allopurinol's inhibition of their metabolism, potentially leading to severe myelosuppression.
- Other interactions include potentiation of warfarin, increased rash with ampicillin/amoxicillin, and increased toxicity of certain cytotoxic agents and thiazide diuretics.
- Careful patient monitoring and education are paramount.
How it Works (Mechanism of Action)
Allopurinol functions as a potent structural analogue of hypoxanthine, a naturally occurring purine. Its primary mechanism of action involves the inhibition of xanthine oxidase, a pivotal enzyme in the purine catabolism pathway. Xanthine oxidase is responsible for the conversion of hypoxanthine to xanthine, and subsequently xanthine to uric acid. By competitively binding to and inhibiting this enzyme, allopurinol effectively blocks the final steps in uric acid production. This leads to a significant reduction in both serum and urinary uric acid concentrations, thereby preventing the formation and deposition of uric acid crystals in joints, kidneys, and other tissues, which are the underlying cause of gout and uric acid nephrolithiasis. Allopurinol's major metabolite, oxypurinol (alloxanthine), also contributes to the inhibitory activity of xanthine oxidase and possesses a considerably longer half-life, prolonging the therapeutic effect. The reduction in uric acid levels also results in an increase in the more soluble precursors, hypoxanthine and xanthine, which are then excreted renally.